Meta-Analysis: Cardiovascular Adverse Events Associated With BRAF and MEK Inhibitors for the Treatment of Melanoma
28 Aug, 2019 | 02:11h | UTCCommentary: Risk of Cardiovascular Adverse Events in Patients With Melanoma Treated With Combined BRAF and MEK Inhibition vs BRAF Inhibition Alone – The ASCO Post (free)